MedTrace Logo

Extra Alirocumab in Addition to Statin Therapy in Symptomatic IntraCranial Atherosclerotic Stenosis ----a Pilot Study

NCT06052020 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2023-09-28

No results posted yet for this study

Summary

The primary goal of the trial is to investigate whether the lipid lowering strategy using Alirocumab plus statin could cause more changes from baseline in intracranial atherosclerotic plaque and hemodynamic features during 6 months of follow-up, in patients with recent stroke/transient ischemic attack (TIA) caused by intracranial artery stenosis.

Conditions

  • Stroke
  • Intracranial Atherosclerotic Stenosis

Interventions

DRUG

Alirocumab

alirocumab (75 mg every 2 weeks)

DRUG

Atorvastatin

Atorvastatin 20-40mg

Sponsors & Collaborators

  • The First Affiliated Hospital with Nanjing Medical University

    lead OTHER

Principal Investigators

  • Kezhong Zhang, MD · The First Affiliated Hospital with Nanjing Medical University

Eligibility

Min Age
30 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-09-15
Primary Completion
2024-09-15
Completion
2024-09-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06052020 on ClinicalTrials.gov